Addex Therapeutics (ADXN), a clinical-stage pharmaceutical company specializing in allosteric modulation, announced that shareholders approved all board proposals at its 2025 Annual General Meeting or AGM, with 30.18% of the company's outstanding capital represented.
Shareholders endorsed the 2024 annual report, financial statements, and result appropriation, while also approving the compensation report in a consultative vote. All proposals related to board and executive management compensation received approval, and discharge was granted to board and executive members for their 2024 activities.
Dr. Vincent Lawton was re-elected as chairman and board member, as well as to the compensation committee. Dr. Raymond Hill was re-elected as a board and committee member, and Dr. Roger Mills, Mr. Tim Dyer, Mr. Jake Nunn, and Dr. Isaac Manke were all reappointed to the board.
BDO SA was re-elected as auditor for 2025, and Robert P. Briner will continue as the independent voting rights representative until the 2026 AGM. Further details are available on Addex's website.
Wednesday, ADXN closed at $9.16, or 3.62% higher on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.